Sawai Pharmaceutical has entered into an exclusive license agreement to develop and distribute Swiss-based Acino Group's oncology product in Japan.
Subscribe to our email newsletter
Acino will be manufacturing the product at its site in Miesbach, Germany, and will supply the product from there.
Acino Group CEO Peter Burema said the alliance between Sawai and Acino will enhance both
companies’ mid-term growth opportunities.
Acino develops and manufactures generic pharmaceuticals like oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, using advanced drug delivery technologies.
Acino also offers services from product development and registration to sourcing, contract
manufacturing, packaging and logistics.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.